News & Updates

Show Multimedia Only

Novel petrelintide shows promise in obesity treatment

Treatment with a once-weekly injectable petrelintide, a novel human amylin analogue, yields up to 10.7 percent weight loss through week 42 in adults with obesity or overweight, according to the phase II ZUPREME-1 trial presented at ADA 2026.

Novel petrelintide shows promise in obesity treatment

8 hours ago

Age-based ivermectin dosing safe, efficacious in children with scabies infection

20 hours ago by

In the treatment of scabies infection in children up to 2 years of age, age-based ivermectin dosing yields high response rates and is well-tolerated, according to the open-label phase 2 ITCHY 2 study.

Age-based ivermectin dosing safe, efficacious in children with scabies infection

20 hours ago

Nivolumab-relatlimab safer than ipilimumab-nivolumab in advanced cutaneous melanoma

21 hours ago

Treatment with nivolumab plus relatlimab results in a lower incidence of severe immune-related adverse events (irAEs), delayed onset of irAEs, and reduced rate of treatment discontinuation among patients with advanced cutaneous melanoma when compared with ipilimumab plus nivolumab, reports a study.

Nivolumab-relatlimab safer than ipilimumab-nivolumab in advanced cutaneous melanoma

21 hours ago

Nirsevimab prevents RSV-related hospitalizations, severe disease in infants

22 hours ago by

Treatment with nirsevimab has been shown to bring down the number of hospitalizations due to respiratory syncytial virus (RSV) infections and prevent the development of severe disease in infants, according to a study presented at ESPID 2026.

Nirsevimab prevents RSV-related hospitalizations, severe disease in infants

22 hours ago

Hospital pharmacists feel not skilled enough to provide care to cancer patients

23 hours ago

Pharmacists working in hospitals do not see themselves competent enough to handle cancer patients, a study has shown.

Hospital pharmacists feel not skilled enough to provide care to cancer patients

23 hours ago

Berobenatide a promising addition to the current GLP-1 RA roster

a day ago by

In the phase II VESPER-2 trial, the investigational injectable glucagon-like peptide-1 receptor agonist (GLP-1 RA) berobenatide shows robust reductions in weight and HbA1c in adults with obesity/overweight and type 2 diabetes (T2D).

Berobenatide a promising addition to the current GLP-1 RA roster

a day ago

Secukinumab improves outcomes in Chinese children with enthesitis-related arthritis

a day ago by

Treatment with secukinumab helps reduce symptoms and disease activity in Chinese children with enthesitis-related arthritis, as shown in a retrospective study.

Secukinumab improves outcomes in Chinese children with enthesitis-related arthritis

a day ago

Glucose-lowering therapy tied to reduced risk of depression in T2D

23 Jun 2026

Exposure to several glucose-lowering drugs appears to have a protective effect on the risk of depression in individuals with type 2 diabetes (T2D), according to a population-based cohort study in Hong Kong.

Glucose-lowering therapy tied to reduced risk of depression in T2D

23 Jun 2026

Eribulin in liposarcoma: Clinical benefit and guideline recommendations

23 Jun 2026 by

Liposarcoma (LPS) is a rare malignant tumour of adipose tissue, characterized by significant heterogeneity and limited systemic treatment options, particularly in advanced stages. At an industry-sponsored symposium, Dr Herbert Loong of the Chinese University of Hong Kong reviewed advances in systemic therapies for LPS, highlighting clinical evidence supporting the use of eribulin in second-line (2L) and later settings. Dr Olivia Chen, on behalf of the Prince of Wales Hospital sarcoma group, presented a local case of LPS treated with eribulin + lenvatinib, which demonstrated durable clinical benefit over 2 years.

Eribulin in liposarcoma: Clinical benefit and guideline recommendations

23 Jun 2026

Ocrelizumab slows hand function decline in multiple sclerosis patients

22 Jun 2026 by

Treatment with ocrelizumab helps delay progression of disability, especially of the upper limb, in a broad population of patients with primary progressive multiple sclerosis (PPMS), including those who are older and have more advanced disease, according to the phase 3b ORATORIO-HAND trial.

Ocrelizumab slows hand function decline in multiple sclerosis patients

22 Jun 2026

News & Updates

Showing Pharmacy articles

Showing

Specialty:

Novel petrelintide shows promise in obesity treatment

Novel petrelintide shows promise in obesity treatment

Age-based ivermectin dosing safe, efficacious in children with scabies infection

Age-based ivermectin dosing safe, efficacious in children with scabies infection

Nivolumab-relatlimab safer than ipilimumab-nivolumab in advanced cutaneous melanoma

Nivolumab-relatlimab safer than ipilimumab-nivolumab in advanced cutaneous melanoma

Nirsevimab prevents RSV-related hospitalizations, severe disease in infants

Nirsevimab prevents RSV-related hospitalizations, severe disease in infants

Hospital pharmacists feel not skilled enough to provide care to cancer patients

Hospital pharmacists feel not skilled enough to provide care to cancer patients

Berobenatide a promising addition to the current GLP-1 RA roster

Berobenatide a promising addition to the current GLP-1 RA roster

Secukinumab improves outcomes in Chinese children with enthesitis-related arthritis

Secukinumab improves outcomes in Chinese children with enthesitis-related arthritis

Glucose-lowering therapy tied to reduced risk of depression in T2D

Glucose-lowering therapy tied to reduced risk of depression in T2D

Eribulin in liposarcoma: Clinical benefit and guideline recommendations

Eribulin in liposarcoma: Clinical benefit and guideline recommendations

Ocrelizumab slows hand function decline in multiple sclerosis patients

Ocrelizumab slows hand function decline in multiple sclerosis patients